Home » Stocks » OncoSec Medical

OncoSec Medical Incorporated (ONCS)

Stock Price: $4.40 USD 0.20 (4.76%)
Updated Aug 3, 2020 1:51 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 101.34M
Revenue (ttm) n/a
Net Income (ttm) -40.78M
Shares Out 23.03M
EPS (ttm) -3.08
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 3, 2020
Last Price $4.40
Previous Close $4.20
Change ($) 0.20
Change (%) 4.76%
Day's Open 4.18
Day's Range 4.11 - 4.54
Day's Volume 310,481
52-Week Range 1.04 - 4.89

More Stats

Market Cap 101.34M
Enterprise Value 78.79M
Earnings Date (est) Dec 10, 2020
Ex-Dividend Date n/a
Shares Outstanding 23.03M
Float 9.18M
EPS (basic) -3.22
EPS (diluted) -3.08
FCF / Share -1.45
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 92,949
Short Ratio 0.48
Short % of Float 1.51%
Beta 2.12
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 4.46
Revenue n/a
Operating Income -40.43M
Net Income -40.78M
Free Cash Flow -31.88M
Net Cash 22.55M
Net Cash / Share 0.98
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -76.22%
ROE -190.23%
ROIC -1,229.40%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 4
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$7.10*
(61.36% upside)
Low
5.00
Current: $4.40
High
10.00
Target: 7.10
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue----------
Operating Income-29.98-36.61-21.45-26.89-21.24-11.95-7.06-5.53-1.70-0.04
Net Income-30.28-39.14-21.45-26.89-21.24-12.01-7.15-2.36-3.76-0.04
Shares Outstanding7.054.012.021.651.270.950.530.340.320.34
Earnings Per Share-4.29-9.75-10.60-16.30-16.70-12.60-13.40-8.00-12.00-
Operating Cash Flow-29.00-23.22-17.34-17.81-17.65-8.98-5.53-4.22-1.31-0.01
Capital Expenditures-0.01-0.07-0.02-1.55-1.43-0.51-0.11-0.05-0.31-
Free Cash Flow-29.01-23.29-17.36-19.36-19.08-9.49-5.65-4.27-1.62-0.01
Cash & Equivalents25.1526.9811.4428.7532.0437.854.975.142.460.00
Total Debt0.08---------
Net Cash / Debt25.0626.9811.4428.7532.0437.854.975.142.460.00
Assets29.8930.2515.2332.4135.5939.396.517.435.67-
Liabilities5.617.324.544.352.891.321.773.008.040.03
Book Value24.2822.9210.7028.0532.7038.074.744.43-2.36-0.03
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name OncoSec Medical Incorporated
Country United States
Employees 37
CEO Daniel J. O'Connor

Stock Information

Ticker Symbol ONCS
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ONCS

Description

OncoSec Medical Incorporated, a biotechnology company, focuses on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. Its lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 for reversing the immunosuppressive microenvironment in the treated tumor. The company is also developing ImmunoPulse IL-12 with KEYTRUDA in patients with advanced melanoma that is in the Phase IIb clinical trials (KEYNOTE-695) and advanced or metastatic triple negative breast cancer (TNBC), which is in the Phase II clinical trials (KEYNOTE-890); ImmunoPulse IL-12 and KEYTRUDA in patients with advanced or metastatic melanoma that has completed Phase II clinical trials; and ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma, which has completed the Phase II clinical trials. In addition, it undertakes the Phase II monotherapy biomarker study in patients with advanced or metastatic TNBC. Further, the company is developing new DNA-encoded therapeutic candidates and tumor indications. It has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890 studies; a collaborative research agreement with Duke University School of Medicine to evaluate TAVOPLUS; a collaboration with Dana-Farber Cancer Institute and the Marasco Laboratory to develop CAR T-cell therapies for triple-negative breast cancer and ovarian cancer; a research collaboration with Roswell Park Comprehensive Cancer Center to evaluate the use of Roswell Park's intravital microscopy and TAVO; and collaboration with Providence Cancer Institute. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. The company was incorporated in 2008 and is headquartered in Pennington, New Jersey.